Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA1 | P14867 | 2/20 | 0.38 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.38 |
| ▸ | EIF4A3 | P38919 | 1/20 | 0.36 |
| ▸ | KDM1A | O60341 | 4/20 | 0.33 |
| ▸ | KDM1B | Q8NB78 | 2/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.31 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.31 |
| ▸ | ADRB2 | P07550 | 2/20 | 0.31 |
| ▸ | CA1 | P00915 | 1/20 | 0.31 |
| ▸ | CA2 | P00918 | 1/20 | 0.31 |
| ▸ | PDE2A | O00408 | 1/20 | 0.31 |
| ▸ | APLNR | P35414 | 2/20 | 0.30 |
| ▸ | RECQL | P46063 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12413927 | 0.91 | GABRA1 (0.38) | GABRA1GABRB1EIF4A3KDM1AKDM1B | |
| SCHEMBL25796892 | 0.88 | GABRA1 (0.39) | GABRA1GABRB1EIF4A3KDM1AKDM1B | |
| SCHEMBL24869449 | 0.86 | GABRA1 (0.38) | GABRA1GABRB1EIF4A3GABRB2ADRB2 | |
| SCHEMBL15706603 | 0.82 | LMNA (0.38) | GABRA1GABRB1EIF4A3KDM1AKDM1B | |
| SCHEMBL13319560 | 0.82 | EIF4A3 (0.41) | GABRA1GABRB1EIF4A3GABRB2ADRB2 | |
| SCHEMBL26832324 | 0.80 | AHR (0.35) | GABRA1GABRB1EIF4A3KDM1AKDM1B | |
| SCHEMBL12868984 | 0.80 | GABRA1 (0.43) | GABRA1GABRB1GABRB2ADRB2CA1 | |
| SCHEMBL14629520 | 0.80 | GABRA1 (0.43) | GABRA1GABRB1EIF4A3GABRB2ADRB2 | |
| SCHEMBL1911426 | 0.79 | EIF4A3 (0.40) | GABRA1GABRB1EIF4A3GABRB2ADRB2 | |
| SCHEMBL12173270 | 0.79 | EIF4A3 (0.42) | GABRA1GABRB1EIF4A3GABRB2ADRB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200197408-A1 | OXADIAZEPINONE DERIVATIVES AND METHODS OF TREATING HEPATITIS B INFECTIONS | NOVIRA THERAPEUTICS, INC. | 2020-06-25 | — | — | US | disclosed |
| US-9951065-B2 | Benzimidazole and imadazopyridine carboximidamide compounds | GILEAD SCIENCES, INC. (US) | 2018-04-24 | — | — | US | disclosed |
| US-20160333009-A1 | BENZIMIDAZOLE AND IMADAZOPYRIDINE CARBOXIMIDAMIDE COMPOUNDS | GILEAD SCIENCES, INC. | 2016-11-17 | — | — | US | disclosed |
| US-20160333009-A1 | BENZIMIDAZOLE AND IMADAZOPYRIDINE CARBOXIMIDAMIDE COMPOUNDS | GILEAD SCIENCES, INC. | 2016-11-17 | — | — | US | disclosed |
| US-8569310-B2 | Pentafluorosulfur imino heterocyclic compounds as BACE-1 inhibitors, compositions and their use | MERCK SHARP & DOHME CORP. (US) | 2013-10-29 | — | — | US | disclosed |
| US-8563543-B2 | Iminothiadiazine dioxide compounds as bace inhibitors, compositions, and their use | MERCK SHARP & DOHME CORP. (US) | 2013-10-22 | — | — | US | disclosed |
| US-20120195881-A1 | PENTAFLUOROSULFUR IMINO HETEROCYCLIC COMPOUNDS AS BACE-1 INHIBITORS, COMPOSITIONS AND THEIR USE | SCHERING CORPORATION (US) | 2012-08-02 | — | — | US | disclosed |
| US-20120189642-A1 | IMINOTHIADIAZINE DIOXIDE COMPOUNDS AS BACE INHIBITORS, COMPOSITIONS, AND THEIR USE | SCHERING CORPORATION (US) | 2012-07-26 | — | — | US | disclosed |
| WO-2011044187-A1 | IMINOTHIADIAZINE DIOXIDE COMPOUNDS AS BACE INHIBITORS, COMPOSITIONS, AND THEIR USE | SCHERING CORPORATION (US) | 2011-04-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120195881-A1 | PENTAFLUOROSULFUR IMINO HETEROCYCLIC COMPOUNDS AS BACE-1 INHIBITORS, COMPOSITIONS AND THEIR USE | BACE1, APP, BACE2 | GABRA1 281/4885GABRB1 334/4885EIF4A3 1472/4885 |
| US-20160333009-A1 | BENZIMIDAZOLE AND IMADAZOPYRIDINE CARBOXIMIDAMIDE COMPOUNDS | IDO1, IDO2, INMT | GABRA1 1599/4885GABRB1 1206/4885EIF4A3 1081/4885 |
| US-20120189642-A1 | IMINOTHIADIAZINE DIOXIDE COMPOUNDS AS BACE INHIBITORS, COMPOSITIONS, AND THEIR USE | BACE1, APP, BACE2 | GABRA1 4378/4885GABRB1 4370/4885EIF4A3 1147/4885 |
| US-20200197408-A1 | OXADIAZEPINONE DERIVATIVES AND METHODS OF TREATING HEPATITIS B INFECTIONS | HCCS, SLC10A1, PYGL | GABRA1 247/4885GABRB1 92/4885EIF4A3 2166/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.